Samuel R Saks's Net Worth
$37.8 Million
Who is Samuel R Saks?
Samuel R Saks has an estimated net worth of $37.8 Million. This is based on reported shares across multiple companies, which include Auspex Pharmaceuticals, Inc., Cougar Biotechnology, Inc., Trubion Pharmaceuticals, Inc, JAZZ PHARMACEUTICALS INC, Protagonist Therapeutics, Inc, Tonix Pharmaceuticals Holding Corp., PDL BIOPHARMA, INC., and DEPOMED INC.
SEC CIK
Samuel R Saks's CIK is 0001365615
Past Insider Trading and Trends
2007 was Samuel R Saks's most active year for acquiring shares with 22 total transactions. Samuel R Saks's most active month to acquire stocks was the month of October. 2015 was Samuel R Saks's most active year for disposing of shares, totalling 7 transactions. Samuel R Saks's most active month to dispose stocks was the month of April. 2019 saw Samuel R Saks paying a total of $378,150.00 for 188,550 shares, this is the most they've acquired in one year. In 2009 Samuel R Saks cashed out on 45,000 shares for a total of $881,550.00, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Auspex Pharmaceuticals, Inc. No price found
Chief Development Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -67.34K |
—
|
—
|
0
|
May 5
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 2
| |||
Form 4
| +3.53% | 2.17K |
$12.00 | $26,100.00 | 63.84K |
Feb 10
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
Cougar Biotechnology, Inc. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 3
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 12
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
Trubion Pharmaceuticals, Inc No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 28
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 27
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 28
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 25
| |||
Form 3/A
|
—
|
0
|
—
|
—
|
0
| ||||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
JAZZ PHARMACEUTICALS INC (JAZZ) Snapshot price: $107.14
Chief Executive Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 21
| |||
Form 4
| +0.32% | 1.15K |
$1.28 | $1,466.88 | 358.87K |
Nov 28
| |||
Form 4
| +0.38% | 1.34K |
$6.50 | $8,697.00 | 357.72K |
May 30
| |||
Form 4
| +2.53% | 8.79K |
—
|
—
| 356.38K |
May 16
| |||
Form 4
| +0.17% | 590 |
$13.18 | $7,776.20 | 347.59K |
Nov 30
| |||
Form 4
| +1.43% | 4.9K |
$13.40 | $65,642.00 | 347K |
Nov 14
| |||
Form 4
| +7.46% | 23.74K |
$13.42 | $318,454.73 | 342.1K |
Nov 12 - Nov 13
| |||
Form 4
| +33.46% | 79.82K |
—
|
—
| 318.36K |
Jun 6
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
Protagonist Therapeutics, Inc (PTGX) Snapshot price: $41.5
Chief Medical Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
| +600.00% | 12K |
—
|
—
| 14K |
Feb 26
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 28
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 15
| |||
Form 4
|
∞
| 2.5K |
—
|
—
| 2.5K |
Feb 28
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 31
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |